98%
921
2 minutes
20
Introduction: Combining many types of imaging data-especially structural MRI (sMRI) and functional MRI (fMRI)-may greatly assist in the diagnosis and treatment of brain disorders like Alzheimer's. Current approaches are less helpful for forecasting, however, as they do not always blend spatial and temporal patterns from different sources properly. This work presents a novel mixed deep learning (DL) method combining data from many sources using CNN, GRU, and attention techniques. This work introduces a novel hybrid deep learning method combining CNN, GRU, and a Dynamic Cross-Modality Attention Module to help more efficiently blend spatial and temporal brain data. Through working around issues with current multimodal fusion techniques, our approach increases the accuracy and readability of diagnoses.
Methods: Utilizing CNNs and models of temporal dynamics from fMRI connection measures utilizing GRUs, the proposed approach extracts spatial characteristics from sMRI. Strong multimodal integration is made possible by including an attention mechanism to give diagnostically important features top priority. Training and evaluation of the model took place using the Human Connectome Project (HCP) dataset including behavioral data, fMRI, and sMRI. Measures include accuracy, recall, precision and F1-score used to evaluate performance.
Results: It was correct 96.79% of the time using the combined structure. Regarding the identification of brain disorders, the proposed model was more successful than existing ones.
Discussion: These findings indicate that the hybrid strategy makes sense for using complimentary information from several kinds of photos. Attention to detail helped one choose which aspects to concentrate on, thereby enhancing the readability and diagnostic accuracy.
Conclusion: The proposed method offers a fresh benchmark for multimodal neuroimaging analysis and has great potential for use in real-world brain assessment and prediction. Researchers will investigate future applications of this technique to new picture kinds and clinical data.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968424 | PMC |
http://dx.doi.org/10.3389/fnhum.2025.1552178 | DOI Listing |
Stroke
September 2025
Department of Neurology, Yale School of Medicine, New Haven, CT (L.H.S.).
Preclinical stroke research faces a critical translational gap, with animal studies failing to reliably predict clinical efficacy. To address this, the field is moving toward rigorous, multicenter preclinical randomized controlled trials (mpRCTs) that mimic phase 3 clinical trials in several key components. This collective statement, derived from experts involved in mpRCTs, outlines considerations for designing and executing such trials.
View Article and Find Full Text PDFBrain Behav
September 2025
Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
Introduction: Anxiety and stress are prevalent mental health issues. Traditional drug treatments often come with unwanted side effects and may not produce the desired results. As an alternative, probiotics are being used as a treatment option due to their lack of specific side effects.
View Article and Find Full Text PDFCephalalgia
September 2025
Department of Molecular Physiology and Biophysics, University of Iowa, Iowa City, IA, USA.
Migraine is a complex neurological disorder involving multiple neuropeptides that modulate nociceptive and sensory pathways. The most studied peptide is calcitonin gene-related peptide (CGRP), which is a well-established migraine trigger and therapeutic target. Recently, another peptide, pituitary adenylate cyclase-activating polypeptide (PACAP), has emerged as an alternative target for migraine therapeutics.
View Article and Find Full Text PDFRev Med Liege
September 2025
Service de Chimie clinique, CHU Liège, Belgique.
Chronic kidney disease (CKD), heart failure (HF) and atherosclerotic cardiovascular disease (ASCVD) are pathologies that may remain silent for a long time and thus are largely underdiagnosed in clinical practice. The use of biomarkers may help detect people already suffering from these diseases at an early stage or at increased risk to develop them in a near future. The aim of this article is to discuss the place of the assays of albuminuria, natriuretic peptide (BNP/proBNP) and high-sensitivity troponin as well as lipoprotein(a) to help in the diagnosis and prognosis assessment of individuals at risk of presenting or developing a CKD, HF or ASCVD.
View Article and Find Full Text PDFMol Cell Biol
September 2025
Laboratory of Biochemistry, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Mammalian cell membranes contain ether lipids, which include an alkyl chain derived from a fatty alcohol that is produced by fatty acyl-CoA reductases (FARs). There are two mammalian FAR genes, and , and mutations in cause the peroxisomal fatty acyl-CoA reductase 1 disorder (PFCRD), which is accompanied by various symptoms, including neurological disorders. To date, the contributions of and to brain ether lipid production and the molecular mechanism of PFCRD have remained unknown.
View Article and Find Full Text PDF